Skip to main content
Jang Hyeon Eom on Muck Rack

Jang Hyeon Eom

As seen in: Cell Press, Cell Stem Cell
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jang Hyeon

Contact Jang Hyeon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Phase 1/2a clinical trial of hESC-derived dopamine progenitors in Parkinson’s disease

|
By Jin Chang, Kyung Won Chang, Chan Wook Park, Do-Hun Kim, Sanghyun Park, Chul-Yong Park, Jang Hyeon Eom, Seung Taek Nam, Ki-Sang Jo, Mi-Young Jo, Sung Kyoung Choi, Hye-Jin Hur, Sarang Kim, minseok kim, Dae-Sung Kim, Dong-Youn Hwang, Myoung Soo Kim, Inkyung Jung, Jongwan Kim, Phil Lee, Dong-Wook Kim, Myung Soo Cho
| Cell Press Verified
Keywords cell transplantation dose-escalation trial dopaminergic differentiation dopamine progenitor dopamine neurons human embryonic stem cells Parkinson’s disease stem-cell based therapy Introduction Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the selective loss of dopaminergic (DA) neurons in the substantia nigra pars compacta, leading to striatal dopamine depletion and the emergence of motor symptoms.1 Although pharmacological treatments and deep...
Open in Who Shared Issue with article?

Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson's disease

|
By Sanghyun Park, Chan Wook Park, S. Co, Jang Hyeon Eom
| Cell Stem Cell Verified
Highlights • We generated high-purity mDA progenitors from clinical-grade hESCs on a large scale • We validated the safety and efficacy of mDA progenitors in vitro and in vivo • mDA transplantation improved behavior in PD rat models dose-dependently • A phase 1/2a clinical trial (SIT) for PD cell therapy with 12 patients is underway Summary Human embryonic stem cell (hESC)-derived midbrain dopaminergic (mDA) cell transplantation is a promising therapeutic strategy for Parkinson’s disease (PD).
Open in Who Shared Issue with article?
See all 2 articles